Definium Therapeutics (NASDAQ:DFTX) used its full-year 2025 earnings call to highlight impending late-stage clinical ...
Definium Therapeutics' lead asset, DT120 ODT, has received FDA Breakthrough Therapy Designation for generalized anxiety disorder. The company is preparing for potential commercialization by building ...
If Microsoft 365 deployment tool is not working properly, and you see We couldn't find the specified configuration file, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results